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Abstract
Background: The 85-kDa cytosolic phospholipase A2 (cPLA2) mediates arachidonic acid (AA)
release in MDCK cells. Although calcium and mitogen-activated protein kinases regulate cPLA2, the
correlation of cPLA2 translocation and phosphorylation with MAPK activation and AA release is
unclear.
Results: MEK1 inhibition by U0126 inhibited AA release in response to ATP and ionomycin. This
directly correlated with inhibition of ERK activation but not with phosphorylation of cPLA2 on
Ser505, which was only partially inhibited by ERK inhibition. Inhibition of AA release by U0126 was
still observed when stoichiometric phosphorylation of cPLA2 on Ser505 was maintained by
activating p38 with anisomycin. Translocation kinetics of wild-type cPLA2 and cPLA2 containing
S505A or S727A mutations to Golgi were similar in response to ATP and ionomycin and were not
affected by U0126.
Conclusions: These results suggest that the ability of cPLA2 to hydrolyze membrane phospholipid
is reduced by inhibition of the MEK1/ERK pathway and that the reduction in activity is independent
of cPLA2 phosphorylation and translocation to membrane. The results also demonstrate that
cPLA2 mutated at the phosphorylation sites Ser505 and Ser727 translocated with similar kinetic as
wild-type cPLA2.
Background
Cytosolic PLA2 specifically hydrolyzes sn-2 arachidonate
from phospholipid providing the precursors for many dif-
ferent lipid mediators including prostaglandins and leu-
kotrienes [1,2]. These lipid metabolites play a role in acute
inflammatory responses and also regulate normal physio-
logical processes. Certain prostaglandins are required for
female reproduction and kidney function [3–5]. Because
of its important role in controlling levels of arachidonic
acid (AA), much attention has been focused on the regu-
lation of cPLA2 activation, with particular emphasis on
the role of its phosphorylation and Ca2+-mediated trans-
location [6–8].
cPLA2 is regulated by controlling its cellular localization
and access to membrane-phospholipid substrate. An ami-
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no terminal, calcium-dependent lipid binding (CaLB or
C2) domain regulates Ca2+-mediated cPLA2 translocation
to intracellular membranes [9]. In vitro, membrane dock-
ing via the C2 domain is necessary and sufficient for catal-
ysis and release of AA [10]. Binding of calcium ions by the
cPLA2 C2 domain is essential for the lipid association in
vitro [11,12] and translocation in vivo [13,14]. In re-
sponse to an increase in [Ca2+]i, cPLA2 translocates to the
Golgi and ER, however translocation to Golgi occurs at a
lower [Ca2+]i[15].
Protein kinase pathways play major roles in cPLA2 activa-
tion, and regulation by the mitogen-activated protein ki-
nase kinase (MEK) /extracellular-signal regulated kinase
(ERK) signaling pathway has received particular attention.
cPLA2 is phosphorylated by mitogen activated protein
(MAP) kinases, including p42/p44 ERKs and p38, on
Ser505 in vitro [16,17] and in response to receptor stimu-
lation [16,18–21]. In addition to phosphorylation by
MAP kinase, it has been shown that cPLA2 is also phos-
phorylated on Ser727 by MAPK-interacting kinase I (MN-
KI) [22] and on Ser515 by calcium/calmodulin-dependent
protein kinase II [23]. Phosphorylation of these sites may
also play a role in regulating cPLA2 function in certain cell
models.
Phosphorylation of Ser505 has been extensively studied
because it is readily detected due to a characteristic electro-
phoretic mobility shift when analyzed by SDS-PAGE
[13,16]. The importance of Ser505 phosphorylation in reg-
ulating cPLA2 has been demonstrated in different cells
and in vitro models by using cPLA2 containing a S505A
mutation [16,22]. However, the mechanism whereby
Ser505 phosphorylation regulates cPLA2 function has been
elusive. In vitro studies have demonstrated that dephos-
phorylated cPLA2 is catalytically active and that Ser505
phosphorylation increases activity by only ~30 percent
[24]. In contrast, cells expressing the cPLA2 S505A muta-
tion fail to release AA in response to a low dose of calcium
ionophore, but release similar amounts of AA as cells ex-
pressing wild-type cPLA2 in response to high dose iono-
phore [22]. From these studies, it has been suggested that
cPLA2 Ser505 phosphorylation may have a role in regulat-
ing translocation [22]. A previous study demonstrated
translocation of cPLA2 S505A in response to Ca2+ iono-
phore, but did not address the kinetics of translocation,
translocation in response to a physiological agonist, or
differences in targeting [25].
To better understand the regulation of cPLA2 by the
MEK1/ERK pathway and Ca2+, we investigated the effect
of MEK inhibitors on AA release, cPLA2 phosphorylation
of Ser505, cPLA2 translocation kinetics, and [Ca2+]i in-
crease in Madin-Darby canine kidney (MDCK) cells. We
found that inhibition of MEK1 by U0126 significantly in-
hibited AA release and this was correlated with inhibition
of ERK activation. However, MEK inhibition only partially
affected cPLA2 phosphorylation and had no effect on the
kinetics of Ca2+-mediated cPLA2 translocation to mem-
brane. In addition, using cells expressing wild-type cPLA2
and cPLA2 with S505A or S727A mutations, it was found
that translocation kinetics and membrane targeting in re-
sponse to ATP or ionomycin was similar to wild-type
cPLA2. These data suggest that MEK1 inhibition reduces
cPLA2 catalytic activity and AA release independently of
phosphorylation and translocation.
Results
Effect of MEK inhibition on AA release, ERK activation, 
and cPLA2 Ser505 phosphorylation
To study the role of the MEK1/ERK pathway in cPLA2 ac-
tivation, quiesced MDCK cells were treated with the MEK1
inhibitor U0126, and the effect on AA release, ERK activa-
tion, and cPLA2 gel shift determined (Fig. 1). For equiva-
lence with the imaging studies, cells expressing EGFP-
cPLA2 were used in all experiments. EGFP-cPLA2 was ex-
pressed to similar levels as endogenous enzyme but did
not contribute significantly to AA release in stably trans-
fected cells. However, EGFP-cPLA2 is functional since it
dose-dependently catalyzes release of AA when expressed
in cells that lack endogenous cPLA2, such as Sf9 cells [13]
and immortalized mouse lung fibroblasts from cPLA2
knock-out mice [26]. In order to enhance AA release in
cells containing endogenous cPLA2, it is necessary to over-
express the enzyme several fold as previously reported
[16]. Cytosolic PLA2 has been shown to mediate Ca2+-in-
duced AA release in MDCK cells treated with ATP and
IONO in experiments using the group IV cPLA2-specific
inhibitor pyrrolidine-1 [27]. To measure cPLA2 mediated
AA release, EGFP-cPLA2-transfected MDCK cells labeled
with [3H]-AA were incubated with 0.3, 1 or 10 M U0126
for 15 min prior to stimulation with 100 M ATP, 1 M
IONO, or 10 M IONO. AA release was measured at 3 min
because we have shown that ATP- and IONO-stimulated
AA release peaks between 3 to 5 min post-stimulation
[15]. Agonist-induced AA release was inhibited dose-de-
pendently by U0126 (Fig. 1A) with the highest U0126
concentration used (10 M) reducing AA release by 72–
80% with all agonists (Table 1I). This inhibition was in-
dependent of the total amount of AA released, since AA re-
lease stimulated by 10 M IONO was 3-fold greater than
release stimulated with 1 M IONO or 100 M ATP, but
the percent inhibition by U0126 was similar. Treatment of
MDCK cells with 30 M PD098059, a less potent inhibi-
tor of MEK [28,29], resulted in a ~50% reduction in AA re-
lease in response to 100 M ATP, 1 M IONO, and 10 M
IONO (data not shown). Thus, in MDCK cells, MEK1 in-
hibition significantly reduces the ability of cPLA2 to hy-
drolyze AA from membrane phospholipids.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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Figure 1
Effect of MEK inhibition on AA release, ERK inhibition, and cPLA2 Ser505 phosphorylation (A) EGFP-cPLA2-trans-
fected cells were incubated with the indicated concentrations of U0126 for 15 min prior to stimulation with 100 M ATP, 1
M IONO, or 10 M IONO. AA release was assayed at 3 min. Results show the average  SD of 3 experiments (error bars
are down for ATP for clarity). Protein extracts from EGFP-cPLA2-transfected cells incubated with the indicated concentrations
of U0126 for 15 min prior to stimulation with 100 M ATP, 1 M IONO, or 10 M IONO for 3 min were subjected to immu-
noblotting using (B) anti-phospho-ERK and (C) anti-cPLA2 polyclonal antibodies. Results are from 3 to 5 independent experi-
ments.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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The effect of MEK1 inhibition on activation of p42/p44
ERK measured by immunoblot analysis using phospho-
specific antibodies in cells treated with U0126 and stimu-
lated as above was determined (Fig. 1B). Work in our lab-
oratory has shown that recognition of ERK by anti-
phospho-ERK antibodies correlates with an increase in
ERK activity [21,30,31]. Interestingly, the anti-phospho-
ERK immunoblots revealed that ERKs were constitutively
activated in untreated, quiesced MDCK cells and activa-
tion was not enhanced further by ATP or IONO (Fig. 1B,
left panel). ERK activation was diminished by increasing
concentrations of U0126 and was quantitatively inhibited
after 15 min incubation in 10 M U0126. U0126 de-
creased ERK activation following ATP or IONO stimula-
tion in the same fashion as in unstimulated cells.
Consequently, there was a direct correlation between the
reduction of AA release (Fig. 1A) and inhibition of ERK ac-
tivation (Fig. 1B) in MDCK cells treated with U0126.
Because cPLA2 is a target of the MEK1/ERK signaling cas-
cade, we assayed the effect of MEK1 inhibition by U0126
on cPLA2 phosphorylation by analyzing gel shift of cPLA2.
Phosphorylation of Ser505 results in a retardation of its
electrophoretic mobility (gel shift) [13,16]. In unstimulat-
ed cells, EGFP-tagged and endogenous cPLA2 were nearly
completely gel shifted, indicating that most cPLA2 was
phosphorylated on Ser505 (Fig. 1C), which is consistent
with the observation that ERKs are constitutively activat-
ed. Incubation with U0126 resulted in a partial reversal of
the gel shift although, at 10 M U0126, approximately
half of cPLA2 remained phosphorylated on Ser505. Thus,
unlike the quantitative effect of U0126 on ERK activation,
inhibition of MEK1 with U0126 only partially reversed
the gel shift of cPLA2. The reversal of the gel shift was sim-
ilar in cells treated with ATP and 1 and 10 M IONO. Due
to the increased molecular weight of the EGFP-tagged
cPLA2, the two forms of cPLA2 did not separate as well,
making the gel shift more difficult to visualize, but gener-
ally mirrored the gel shift characteristics of the endog-
enous cPLA2. These results suggest that, in response to
MEK1 inhibition, there is a quantitative, dose-dependent
decrease in AA release that correlates well with the loss of
ERK activation, but not with the extent of cPLA2 Ser505
phosphorylation.
To further investigate whether the MEK1/ERK pathway
played a role in regulating AA release independent of
Ser505 phosphorylation, we treated cells with anisomycin,
which activates the MAPK homolog p38, but not the
MEK1/ERK pathway [32]. Activation of p38 in response to
anisomycin treatment was analyzed by immunoblotting
using an anti-phospho-p38 antibody (Fig. 2A). The im-
munoblots demonstrate that 30 min treatment in 25 ng/
ml anisomycin resulted in phosphorylation of p38 in un-
stimulated MDCK cells and in cells treated with ATP or
IONO. ATP and ionomycin treatment in the absence of
anisomycin only weakly increased p38 phosphorylation.
As expected, the MEK inhibitor U0126 did not significant-
ly affect anisomycin-stimulated p38 phosphorylation. In
control experiments, anisomycin treatment did not in-
duce ERK activation nor interfere with inhibition of ERK
activation by 10 M U0126 treatment (Fig. 2B). We have
previously reported that p38 is also selectively activated in
anisomycin-treated macrophages [21]. Importantly, pre-
treatment of cells for 30 min with anisomycin resulted in
maintenance of the cPLA2 gel shift in the presence of
U0126 in unstimulated cells and in cells stimulated with
ATP and 1 and 10 M IONO (Fig. 2C). AA release assays
show that, in MDCK cells treated with anisomycin, U0126
resulted in an AA release reduction of ~67–76% (Fig. 2D)
similar to the inhibition observed without anisomycin.
These results demonstrate that activation of the MEK1/
ERK pathway is required for AA release even under condi-
tions where cPLA2 Ser505 phosphorylation is maintained,
suggesting an alternative role for the MEK1/ERK pathway
in regulating cPLA2.
[Ca2+]i increase is independent of MEK1/ERK pathway
One explanation for the decrease in AA is that U0126 in-
hibits [Ca2+]i mobilization in response to ATP or IONO,
thereby preventing translocation of cPLA2. In chick ven-
tricular myocytes, inhibition of MEK1/ERK by PD98059
inhibits zinterol-mediated AA release, but also inhibits
zinterol-induced stimulation of [Ca2+]i cycling in electri-
cally stimulated cells [33]. In MDCK cells, extracellular
ATP acts via P2Y2 receptors to elicit an IP3-mediated
[Ca2+]i increase [34] and IONO acts to increase [Ca2+]i by
permeabilizing cell membranes to Ca2+. To determine the
effect of U0126 on intracellular Ca2+ mobilization by 100
M ATP or 10 M IONO, we utilized single-cell fluores-
cence microscopy on cells loaded with the calcium indica-
tor Fura2. Analysis of the [Ca2+]i increase in individual
cells reveals the heterogeneity in the response to ATP, al-
though most cells exhibited [Ca2+]i spikes of similar mag-
nitude and duration (Fig. 3A and 3B, thin lines). Analysis
of the [Ca2+]i increase in several cells (Fig. 3A and 3B,
Table 1: Inhibition of AA release by 10 M U0126 See "Experimen-
tal Procedures" for experimental conditions and methods to de-
termine AA release. Percent inhibition of AA release after 3 min 
of agonist treatment are average  S.D. for N experiments pre-
formed in duplicate.
Agonist % Inhibition N
100 M ATP 76.1  6.8 7
1 M IONO 80.2  5.9 8
10 M IONO 72.2  7.3 6BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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Figure 2
Effect of anisomycin and U0126 on AA release, ERK inhibition, and cPLA2 Ser505 phosphorylation EGFP-cPLA2-
transfected cells were incubated with 25 ng/ml anisomycin for 30 min, 10 M U0126 for 15 min, or with both drugs prior to
stimulation with 100 M ATP, 1 M IONO, or 10 M IONO. Protein extracts were subjected to immunoblotting using (A)
anti-phospho-p38, (B) anti-phospho-ERK, and (C) anti-cPLA2 antibodies. (D) AA release in response to 100 M ATP, 1 M
IONO, or 10 M IONO in the presence and absence of the inhibitors. Anisomycin did not stimulate AA release in unstimu-
lated cells. The results show average  SEM for 3 to 5 independent experiments.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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thick line) revealed that although the duration of the
[Ca2+]i increase elicited by ATP in control cells was the
same as in the U0126-treated cells, approximately 3–4
min, the amplitude of the [Ca2+]i increase was slightly
higher (~20%) in the U0126-treated cells. IONO elicited
a sustained, supraphysiological [Ca2+]i increase in cells
that was also slightly enhanced by U0126 (Fig. 3C and
3D). These experiments demonstrate that U0126 does not
decrease [Ca2+]i mobilization, and the inhibition of AA
release by U0126 cannot be ascribed to a failure in [Ca2+]i
mobilization.
cPLA2 translocation is independent of MEK1/ERK pathway
The effect of inhibition of the MEK1/ERK pathway by
U0126 on translocation of cPLA2 was investigated. Al-
though there is no inhibition of [Ca2+]i release by U0126
and little effect on Ser505 phosphorylation, it is possible
that MEK1 inhibition by U0126 prevents cPLA2 transloca-
tion by another mechanism. To investigate this possibili-
ty, cells were transfected with a wild-type cPLA2 fused to
EYFP (EYFP-cPLA2) and the distribution of EYFP-cPLA2
was imaged in response to [Ca2+]i transients elicited by
ATP and sustained [Ca2+]i elevations elicited by IONO, in
the presence and absence of U0126. Following stimula-
tion with 100 M ATP, there was a rapid translocation of
EYFP-cPLA2 to Golgi that was unaffected by U0126 (Fig.
4A,4B). In response to physiological agonists that elicit
transient [Ca2+]i changes, only a small fraction of the
cPLA2 translocates. This observation is consistent with our
previous results [15] and has been demonstrated by Hira-
Figure 3
Effect of U0126 on ATP- and IONO-induced [Ca2+]i change MDCK cells were loaded with the fluorescent Ca2+ indi-
cator Fura2, incubated with 10 M U0126 or vehicle for 15 min, and stimulated with 100 M ATP or 10 M IONO. Graphs
show changes in [Ca2+]i (expressed as the 340/380 ratio of Fura2 fluorescence) with respect to time from 8 individual cells
(thin traces) and from the average of 16 cells (thick trace) treated with (A) U0126 and ATP, (B) vehicle and ATP, (C) U0126
and IONO, and (D) vehicle and IONO. Results are representative of 4 independent experiments in each condition and analysis
of several cells per experiment.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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bayashi et al. [35]. Most studies of cPLA2 translocation
have utilized ionophore, which elicits a large, supraphys-
iological sustained increase in [Ca2+]i[14,15,25,35–38],
or agonists that produce a sustained [Ca2+]i increase[35].
Under these conditions, a large proportion of cPLA2 binds
to membrane. These studies show extensive translocation
to the endoplasmic reticulum (ER), nuclear envelope and
Golgi [14,15,35,36,38]. We found that U0126 also failed
to alter extensive EYFP-cPLA2 translocation to Golgi and
ER in response 10 M IONO (Fig. 4C,4D). These results
demonstrate that MEK inhibition has no effect on cPLA2
translocation.
Translocation of phosphorylation site mutants S505A or 
S727A is similar as wild-type cPLA2
Phosphorylation of cPLA2 on Ser505 has been hypothe-
sized to play a role in Ca2+-mediated translocation since
Ser505 phosphorylation is required for cPLA2-mediated
AA release in response to low-dose, but not high-dose,
ionophore [22]. Translocation of cPLA2 S505A in CHO
cells has been reported in response to ionophore stimula-
tion [25], but the effect of Ser505 phosphorylation on the
kinetics of translocation, targeting, and in response to a
physiological agonist was not investigated. MDCK cells
were co-transfected with EYFP-cPLA2 and a cPLA2 with a
S505A mutation fused to ECFP (ECFP-cPLA2S505A). Us-
ing dual EYFP/ECFP imaging, we were able to directly
compare translocation of both constructs in the same cell.
The resting distribution of EYFP-cPLA2 was similar to that
of ECFP-cPLA2S505A and, in response to ATP followed by
IONO, the pattern of translocation of EYFP-cPLA2 was
similar to ECFP-cPLA2S505A (Fig. 5 panels A and B, D).
Analysis of the increase in fluorescence at the Golgi with
respect to time demonstrates that the rates of transloca-
tion of cPLA2 and cPLA2S505A elicited by ATP followed
by IONO are very similar (Fig. 5C). As previously reported
[22], the cPLA2 S727A mutation has a similar phenotype
on AA release as the S505A mutation and Ser727 was
found to be phosphorylated in tandem with Ser505. Imag-
ing experiments were performed using EYFP-cPLA2 and
ECFP-cPLA2S727A and we found that the distribution of
EYFP-cPLA2 was identical to that of ECFP-cPLA2S727A be-
fore and after stimulation with 10 M IONO (Fig. 7 pan-
els A and B, D). Analysis of the increase in fluorescence at
the Golgi with respect to time demonstrates that the rates
of translocation of cPLA2 and the cPLA2S727A elicited by
IONO are very similar (Fig. 6C).
Discussion
The MEK1/ERK pathway regulates cPLA2 and ERKs phos-
phorylate cPLA2 on Ser505. The results of this study dem-
onstrate that this pathway is required for cPLA2-mediated
AA release independent of Ser505 phosphorylation and ex-
tend our previous work in macrophages [13] by demon-
strating that this alternative role of the MEK1/ERK
pathway is not involved in regulating [Ca2+]i change or
cPLA2 translocation kinetics or targeting, but is required
for optimal hydrolytic activity and AA release.
The results shown here demonstrate that inhibition of
MEK with U0126 quantitatively inhibits both ERK phos-
phorylation and AA release in MDCK cells in response to
[Ca2+]i mobilization. The MEK inhibitor PD098059, a
less potent inhibitor [28,29], also inhibited ATP- and
IONO-induced AA release (data not shown). ERK was
found to be constitutively phosphorylated in our study
using MDCK cells from ATCC, in contrast to what has
been reported previously for MDCK-D1, a subclone of
Figure 4
Effect of U0126 on translocation of EYFP-cPLA2 fol-
lowing ATP or IONO stimulation Cells expressing
EYFP-cPLA2 were incubated with 10 M U0126 (B, D) or
vehicle (A, C) for 15 min prior to stimulation with 100 M
ATP (A, B) or 10 M IONO (C, D). Representative frames
from time-lapse images show the distribution of EYFP-cPLA2
fluorescence before and after stimulation. Results are repre-
sentative of 4 independent experiments and analysis of sev-
eral cells per experiment.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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MDCK selected for adrenergic receptor expression
[39,40]. However, a side-by-side comparison of MDCK
cells from ATCC and the MDCK-D1 subclone (kindly pro-
vided by Dr. Paul Insel, UCSD) demonstrated constitutive
activation of ERKs when both are grown at low density
(not shown). However, at high density ERKs are less active
and can be further activated by phorbol ester (not shown).
In MDCK-D1 cells, without constitutively active ERKs, AA
release is delayed after [Ca2+]i mobilization, and is tem-
Figure 5
Translocation of ECFP-cPLA2S505A following ATP and IONO stimulation Cells expressing ECFP-cPLA2S505A and
EYFP-cPLA2 were stimulated with ATP and IONO. ECFP and EYFP fluorescence images were taken at 3 s intervals. Represent-
ative frames from time-lapse images show the distribution of EYFP-cPLA2 and ECFP-cPLA2S505A fluorescence before and 30 s
after addition of 100 M ATP, followed by addition of 10 M IONO at 1 min (panels A and B). (C) Fluorescent protein (FP) flu-
orescence from the area of the Golgi (inset) was analyzed with respect to time before and after ATP and IONO addition
(arrows). (D) Overlay of the 75 s images from panels A and B. Results are representative of 5 independent experiments and
analysis of several cells per experiment.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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porally correlated with ERK activation [40], whereas in
MDCK cells with constitutively active ERKs, AA release is
rapid, with significant AA release measured 30 s after
[Ca2+]i increase [15]. This temporal correlation between
AA release and ERK activation has also been reported in
CHO cells in response to PAF stimulation [35,41]. These
results support the observations made here that ERK activ-
ity is required for phospholipid hydrolysis independently
of cPLA2 translocation.
cPLA2-mediated AA release must be preceded by translo-
cation of the enzyme to its membrane substrate which is
a Ca2+-dependent process and is a function of the calci-
um-dependent lipid-binding (C2) domain. cPLA2 translo-
cates primarily to Golgi in response to a transient [Ca2+]i
Figure 6
Translocation of ECFP-cPLA2S727A following IONO stimulation Cells expressing ECFP-cPLA2S727A and EYFP-
cPLA2 were stimulated with IONO. Representative frames from time-lapse images show the distribution of EYFP-cPLA2 and
ECFP-cPLA2S727A fluorescence before and 13 s after addition of 10 M IONO (panels A and B). (C) Fluorescent protein (FP)
fluorescence from the area of the Golgi (inset) was analyzed with respect to time before and after IONO addition (arrow). (D)
Overlay of the 77 s images from panels A and B. Results are representative of 4 independent experiments and analysis of sev-
eral cells per experiment.BMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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changes and to Golgi and ER in response to a sustained
[Ca2+]i increase [15]. The reduction in AA release by MEK
inhibition did not involve a failure in [Ca2+]i release or
translocation. These results show that translocation is nec-
essary but not sufficient for optimum hydrolytic activity.
Measuring cPLA2 translocation is not a trivial matter when
investigating mechanisms of AA release. For example,
cPLA2 constructs with a S505A mutation have long been
recognized as unable to support AA release in response to
physiological agonists or low-dose ionophore when trans-
fected in cells. In contrast, cPLA2 S505A is active in vitro
and phosphorylation only modestly increases the activity
of the enzyme [16,17,24]. Interestingly, the inhibitory ef-
fect of the S505A mutation on AA release is obviated by a
high [Ca2+]i increase. In light of these observations, it is
possible that Ser505 phosphorylation may alter the [Ca2+]i
sensitivity of the enzyme, its rate of translocation, its intra-
cellular targeting or, as has been previously suggested
[22], the ability of cPLA2 to release from a non-membrane
sequestering agent. Although one report has shown that
cPLA2 S505A translocates in CHO cells in response to
ionophore, we were able to directly compare rates of
translocation between cPLA2 and cPLA2 S505A to a phys-
iological agonist and found no difference between trans-
location rates or intracellular targeting. We also
demonstrated that there was no difference in transloca-
tion rates or intracellular targeting between wild-type
cPLA2 and cPLA2 S727A, which has the same phenotype
as S505A with regard to AA release when transfected into
cells. Thus, the role of cPLA2 phosphorylation in mediat-
ing AA release remains unclear.
Although the alternative mechanism whereby the MEK1/
ERK pathway regulates cPLA2 is not known, it is possible
that it affects membrane properties and/or cPLA2 confor-
mation that promotes optimal hydrolytic activity. It is
also possible that the alternative mechanism is due to
phosphorylation of cPLA2 on a novel site by a kinase that
is downstream of the MEK1/ERK pathway or phosphor-
ylation of a regulatory protein.
Conclusions
Translocation to membrane is a critical regulatory step for
the action of cPLA2 because it is necessary for access to
substrate. In this study we demonstrate, however, that as-
sociation of cPLA2 with membrane when phosphorylated
on Ser505 is not sufficient for its full activity in vivo. This
is demonstrated by the results showing that inhibition of
the MEK1/ERK pathway significantly blocks AA release
but has no effect on [Ca2+]i mobilization or cPLA2 trans-
location and targeting. Diminution of AA release by
MEK1/ERK is also independent of cPLA2 phosphorylation
on Ser505. Consequently, our results demonstrate in living
cells that the translocation process and subsequent cata-
lytic activity on the membrane are two independently reg-
ulated steps.
Materials and Methods
Fluorescent protein-cPLA2 fusion constructs
DNA encoding the full-length human cPLA2 was cloned
into the vector pEGFP-C3 (Clontech) to create pEGFP-
cPLA2, as previously described [15]. The XbaI/PstI frag-
ment from a cPLA2 clone containing S505A or S727A
mutations [13] was inserted into an XbaI/PstI site in
pEGFP-cPLA2 to generate pEGFP-cPLA2S505A and
pECFP-cPLA2S727A. Different fluorescent-protein tagged
constructs were produced by exchanging the NheI/BsrGI
fragment containing the fluorescent protein coding se-
quence between EGFP, EYFP, and ECFP. All constructs
were confirmed by sequencing.
Cell culture
MDCK cells obtained from ATCC were cultured in DMEM
containing 10% FBS, 100 U/ml penicillin, 100 g/ml
streptomycin, 0.292 mg/ml glutamine (growth medium)
in 5% CO2 at 37C. Subconfluent cells (5  103 cells/cm2)
were transfected with 2 g of the relevant plasmid using
Fugene-6 (Boehringer Mannheim) in DMEM containing
0.2% BSA, 100 U/ml penicillin, 100 g/ml streptomycin,
0.292 mg/ml glutamine (serum-free medium) following
the manufacturer's protocol. Stable lines expressing EGFP-
cPLA2 were generated by growing transfected cells in
growth medium for 3 d, supplementing the growth medi-
um with 5 mg/ml Geneticin (antibiotic G418-sulfate),
and culturing for an additional 2 wk in Geneticin. Cells
expressing EGFP fluorescence were selected using a fluo-
rescence-activated cell sorter. The EGFP-positive cells were
maintained in growth medium supplemented with 5 mg/
ml Geneticin. For imaging studies, MDCK cells were plat-
ed on glass-bottomed 35 mm culture dishes (MatTek) at 5
 103 cells/cm2 in growth medium and incubated over-
night, transfected with the relevant plasmid(s), changed
into serum-free medium to quiesce the cells, incubated
overnight, and used the next day.
Immunoblotting
Stable EGFP-cPLA2 transfectants were grown on 100 mm
dishes at 5  103 cells/cm2 in growth medium for one day,
then quiesced in serum-free medium overnight. Cells
were scraped into ice-cold lysis buffer: 50 mM HEPES, pH
7.4, 150 mM sodium chloride, 1.5 mM magnesium chlo-
ride, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 200 M
sodium vanadate, 10 mM tetrasodium pyrophosphate,
100 mM sodium fluoride, 10 g/ml leupeptin, and 10 g/
ml aprotinin. Lysates were centrifuged at 15,000  g for 15
min, and protein concentration of the supernatant was
determined by the bicinchoninic acid method. Laemmli
electrophoresis sample buffer (5) was added to the
lysates, and SDS-polyacrylamide gel electrophoresis andBMC Biochemistry 2002, 3 http://www.biomedcentral.com/1471-2091/3/30
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immunoblotting were performed using 35 g lysate pro-
tein, phospho-specific antibodies for ERK and p38, and
rabbit polyclonal antibody for cPLA2[21].
Dual imaging microscopy of fluorescent protein transloca-
tion
In order to compare the characteristics of full-length
cPLA2 and cPLA2S505A or cPLA2S727A translocation,
while controlling for cell-to-cell heterogeneity, we used a
dual CFP/YFP imaging approach. EYFP-cPLA2/ECFP-
cPLA2S505A- or pECFP-cPLA2S727A-transfected MDCK
cells grown on MatTek plates were quiesced overnight in
serum-free medium, washed with and incubated in
Hank's balanced salt solution (HBSS) additionally buff-
ered with 25 mM HEPES pH 7.4 (HHBSS). Cells were im-
aged using an Olympus inverted microscope equipped
with a 60, 1.25 NA oil immersion objective, CFP and YFP
emission filters (Chroma) in a Sutter filter wheel, a dual
CFP/YFP dichroic mirror, and a TILL Imago CCD camera
(TILL Photonics). Excitation light of 430 and 510 nm for
CFP and YFP, respectively, was provided using a Poly-
chrome IV monochromator (TILL Photonics). TILLvisION
software was used for acquisition and analysis. Bleach val-
ues for ECFP and EYFP were calculated by determining the
background-corrected fluorescence for the entire cell with
respect to time and normalizing each value to the initial
value. ECFP/EYFP fluorescence changes with respect to
time for regions of interest corresponding to an area of
Golgi membrane were determined by calculating the Ft/
F0, where Ft is the background- and bleach-corrected ECFP
or EYFP fluorescence at time = t and F0 is the background-
corrected ECFP or EYFP fluorescence at time = 0 s. Fluores-
cence was normalized to the F0 value, which resulted in
Ft/F0 representing the fraction of total cell fluorescence at
Golgi. Final images were produced using Adobe Pho-
toshop.
Calcium imaging
MDCK cells grown on MatTek plates were quiesced over-
night in serum-free medium, washed with HHBSS con-
taining 1 mM probenecid and incubated with 5 M Fura2-
AM (Calbiochem) in HHBSS, 1 mM probenecid, and 1%
DMSO for 45 min at 37C. Cells were then washed with
HHBSS containing 1 mM probenecid and imaged after a
30 min incubation for de-esterification of the Fura2-AM.
Single-cell imaging was performed on the Olympus sys-
tem described above, but using a 40, 1.35 NA oil immer-
sion objective and a Fura2 dichroic mirror and emission
filter (Chroma). Fura2 image pairs illuminated at 340 and
380 nm were taken at 1 Hz. The [Ca2+]i increase is ex-
pressed as the ratio of the background-corrected Fura2 flu-
orescence at 340 and 380 nm [42].
Measurement of AA release
The protocol for determining AA release is essentially as
described [15,21]. MDCK cells stably expressing EGFP-
cPLA2 were plated in 12-well plates at 5  103 cells/cm2
and incubated in growth medium overnight. Cells were
then washed twice with serum-free medium and incubat-
ed with 0.25 Ci [3H]-AA/well in serum-free medium
overnight. U0126 or vehicle was added to each well and
the cells were then incubated for 15 min at 37C in 5%
CO2. Cells were washed to remove unincorporated [3H]-
AA and then incubated in HHBSS supplemented with
0.05% BSA with either U0126 or vehicle. Cells were stim-
ulated with the agonist of choice and the medium was col-
lected at appropriate time points. The medium was
centrifuged at 500 g for 5 min, and the amount of radio-
activity in the supernatant was determined by scintillation
counting. Cells were scraped in 0.5 ml 0.1% Triton X-100
for determining the total cellular radioactivity.
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